

Amendments to the Claims

1.-3. (cancelled)

4. (currently amended) ~~The method according to claim 1,~~ A method of treating headache or migraine in a patient comprising administering a therapeutic amount of a rizatriptan condensation aerosol to the patient by inhalation,

wherein said the therapeutic amount of a rizatriptan condensation aerosol comprises between 1 mg and 20 mg of rizatriptan delivered in a single inspiration, and

wherein the condensation aerosol is formed by heating a thin layer containing rizatriptan, on a solid support, to produce a vapor of rizatriptan, and condensing the vapor to form a condensation aerosol characterized by less than 10% rizatriptan degradation products by weight, and an MMAD of less than 5 microns.

5. (currently amended) ~~The method according to claim 1,~~ A method of treating headache or migraine in a patient comprising administering a therapeutic amount of a zolmitriptan condensation aerosol to the patient by inhalation,

wherein said the therapeutic amount of a zolmitriptan condensation aerosol comprises between 0.5 mg and 10 mg of zolmitriptan delivered in a single inspiration, and

wherein the condensation aerosol is formed by heating a thin layer containing zolmitriptan, on a solid support, to produce a vapor of zolmitriptan, and condensing the vapor to form a condensation aerosol characterized by less than 10% zolmitriptan degradation products by weight, and an MMAD of less than 5 microns.

6.-7. (cancelled)

8. (currently amended) ~~A method of administering a dose form of rizatriptan or zolmitriptan to a patient to achieve a peak plasma drug concentration rapidly, comprising administering to the patient by inhalation an aerosol of rizatriptan or zolmitriptan having less than 5% rizatriptan or zolmitriptan products to a patient comprising administering the dose form to the patient by inhalation,~~

wherein the dose form comprises less than 4 mg of rizatriptan, and

wherein the dose form further comprises a condensation aerosol formed by heating a thin layer containing rizatriptan, on a solid support, to produce a vapor of rizatriptan, and condensing the vapor to form a condensation aerosol characterized by less than 10% rizatriptan degradation products by weight,

and an MMAD of less than 5 microns. ~~3 microns wherein the peak plasma drug concentration is achieved in less than 0.1 hours.~~

9.-16. (cancelled)

17. (new) A method of administering a dose form of zolmitriptan to a patient comprising administering the dose form to the patient by inhalation,
wherein the dose form comprises less than 1 mg of zolmitriptan, and
wherein the dose form further comprises a condensation aerosol formed by heating a thin layer containing zolmitriptan, on a solid support, to produce a vapor of zolmitriptan, and condensing the vapor to form a condensation aerosol characterized by less than 10% zolmitriptan degradation products by weight, and an MMAD of less than 5 microns.

18. (new) A method of administering a rizatriptan condensation aerosol to a patient comprising administering the rizatriptan condensation aerosol to the patient by inhalation, wherein the rizatriptan condensation aerosol is formed by heating a thin layer containing rizatriptan, on a solid support, to produce a vapor of rizatriptan, and condensing the vapor to form a condensation aerosol characterized by less than 5% rizatriptan N-oxide or didehydro rizatriptan by weight, and an MMAD of less than 5 microns.

19. (new) A method of administering a zolmitriptan condensation aerosol to a patient comprising administering the zolmitriptan condensation aerosol to the patient by inhalation, wherein the zolmitriptan condensation aerosol is formed by heating a thin layer containing zolmitriptan, on a solid support, to produce a vapor of zolmitriptan, and condensing the vapor to form a condensation aerosol characterized by less than 5% zolmitriptan N-oxide or didehydro zolmitriptan by weight, and an MMAD of less than 5 microns.